TOPICS: Track 1: Commercialisation

• Deals, mergers and acquisitions: what have we learnt and where are we going in 2022?
• The rise of allogeneic cells
• Evidence, pricing & market access
• Investment, commercialisation and BD
• What we learned about logistics and transportation during COVID
• Regulatory session for academic and early-stage companies
• Tackling large-scale, commercial regulatory challenges
   

TOPICS: Track 2: Latest developments

• What have we learned from COVID and how is the industry moving forward? 
• Remote trials became a reality in 2020, what next?
• How prevent deaths and ensure future clinical success
• Tackling solid tumours
• Next generation of gene therapy 
• Immunogenicity for gene therapy
• Cord blood advancements
• MSCs vs iPSCs for major disease
• Novel next generation gene editing
• Rare disease & orphan drugs

TOPICS: Track 3: Manufacture & bioprocess

• How can advances in COVID vaccine manufacture help us move forward?
• How POC patient delivery needs to develop in the next 5 years
• Cell therapy manufacturing
• Closed systems and automated manufacture.
• Scaling up manufacture to a commercial level
• Effective process development and keeping costs low
• Viral vector analytics and safe manufacture